Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

197
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
197
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

332
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
332
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

284
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
284
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

232
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
232
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

292
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
292

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testing strategy in phase 3 trials with multiple doses.

Biometrical journal. Biometrische Zeitschrift·2018
Same author

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia.

JMIR mHealth and uHealth·2017
Same author

Testing each hypothesis marginally at alpha while still controlling FWER: how and when.

Statistics in medicine·2012
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Changes are still needed on multiple co-primary endpoints.

Christy Chuang-Stein1, Jianjun David Li2

  • 1Chuang-Stein Consulting, LLC, U.S.A.

Statistics in Medicine
|July 20, 2017
PubMed
Summary
This summary is machine-generated.

This commentary questions the application of the US Food and Drug Administration's (FDA) draft guidance on multiple endpoints in clinical trials for safety studies. It addresses power loss with multiple co-primary endpoints and proposes solutions for more effective drug assessment.

Keywords:
average Type I error ratebalanced adjustment methodmin testnon-monotone teststrong Type I error rate control

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Regulatory Science

Background:

  • The US Food and Drug Administration (FDA) issued draft guidance on Multiple Endpoints in Clinical Trials in January 2017.
  • The guidance addresses technical implementation but raises questions regarding its application to safety-focused studies.
  • Multiple co-primary endpoints are often required by regulators for certain disorders.

Purpose of the Study:

  • To question the application of the FDA's draft guidance on multiple endpoints in clinical trials for safety studies.
  • To address the issue of power loss associated with the standard 'min test' for multiple co-primary endpoints.
  • To propose a new approach to enhance statistical power and reflect product effectiveness across multiple, unrelated endpoints.

Main Methods:

  • Review of existing approaches to mitigate power loss in clinical trials with multiple co-primary endpoints.
  • Analysis of the 'min test' and its limitations when applied to more than two co-primary endpoints.
  • Proposal of a novel methodology for assessing drugs with multiple, equally important, and unrelated endpoints.

Main Results:

  • The standard 'min test' for multiple co-primary endpoints leads to significant power loss when the number of endpoints exceeds two.
  • Existing methods to address power loss are reviewed.
  • A new approach is proposed to improve the assessment of drugs with multiple co-primary endpoints.

Conclusions:

  • The current draft guidance's principles may not be optimally applied to safety-focused clinical trials.
  • There is a need for methodological advancements to overcome power limitations in trials with multiple co-primary endpoints.
  • A path forward is urged that utilizes differentiated claims to accurately represent product efficacy across diverse endpoints.